Literature DB >> 11576799

The impact of delirium on the circadian distribution of breakthrough analgesia in advanced cancer patients.

B Gagnon1, P G Lawlor, I L Mancini, J L Pereira, J Hanson, E D Bruera.   

Abstract

Most cancer patients will experience pain requiring opioid therapy during their illness. Standard opioid therapy includes fixed scheduled doses and so-called "rescue" doses for breakthrough pain. Circadian rhythms seem to influence the expression of pain and the responsiveness to analgesic medication. Delirium is a common complication in advanced cancer patients and it also may modify the expression of pain and the use of analgesic medication. We reviewed the circadian distribution of breakthrough analgesia (BTA) doses in 104 advanced cancer patients who were part of a prospective study of the occurrence of delirium. We found that the circadian distribution of BTA is significantly different from a random distribution in the case of patients with and without delirium. Patients without delirium tended to use more BTA (P < 0.001) in the morning, whereas patients with delirium tended to use more BTA in the evening and at night (P = 0.02). We conclude that delirium is associated with changes in the circadian distribution of BTA, which is possibly related to reversal of the normal circadian rhythm.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11576799     DOI: 10.1016/s0885-3924(01)00339-6

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  7 in total

Review 1.  The psychiatric management of end-of-life pain and associated psychiatric comorbidity.

Authors:  B Eliot Cole
Journal:  Curr Pain Headache Rep       Date:  2003-04

2.  Pre- and post-transplantation risk factors for delirium onset and severity in patients undergoing hematopoietic stem-cell transplantation.

Authors:  Jesse R Fann; Rebecca A Hubbard; Catherine M Alfano; Sari Roth-Roemer; Wayne J Katon; Karen L Syrjala
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

Review 3.  Evidence-based treatment of delirium in patients with cancer.

Authors:  William Breitbart; Yesne Alici
Journal:  J Clin Oncol       Date:  2012-03-12       Impact factor: 44.544

4.  Melatonin intervention to prevent delirium in hospitalized patients: A meta-analysis.

Authors:  Wei You; Xiao-Yu Fan; Cheng Lei; Chen-Cong Nie; Yao Chen; Xue-Lian Wang
Journal:  World J Clin Cases       Date:  2022-04-26       Impact factor: 1.534

5.  Preventing Delirium at the End of Life: Lessons From Recent Research.

Authors:  Donna B. Greenberg
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2003-04

6.  Glucocorticoid regulation of ATP release from spinal astrocytes underlies diurnal exacerbation of neuropathic mechanical allodynia.

Authors:  Satoru Koyanagi; Naoki Kusunose; Marie Taniguchi; Takahiro Akamine; Yuki Kanado; Yui Ozono; Takahiro Masuda; Yuta Kohro; Naoya Matsunaga; Makoto Tsuda; Michael W Salter; Kazuhide Inoue; Shigehiro Ohdo
Journal:  Nat Commun       Date:  2016-10-14       Impact factor: 14.919

7.  Melatonin to prevent delirium in patients with advanced cancer: a double blind, parallel, randomized, controlled, feasibility trial.

Authors:  Peter G Lawlor; Marie T McNamara-Kilian; Alistair R MacDonald; Franco Momoli; Sallyanne Tierney; Nathalie Lacaze-Masmonteil; Monidipa Dasgupta; Meera Agar; Jose L Pereira; David C Currow; Shirley H Bush
Journal:  BMC Palliat Care       Date:  2020-10-21       Impact factor: 3.234

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.